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Introduction: Resectional surgery remains the mainstay of treatment for colorectal cancer. A heightened post-
operative systemic inflammatory response has been shown to correlate negatively with short/long-term out-
comes. Perioperative steroid administration may help to alleviate this systemic inflammatory response. This
survey has been carried out to assess current attitudes towards perioperative steroid use and to gauge interest in
a randomised control trial in this area.
Method: An internet-based survey consisting of 9 questions was circulated via email. Those responses from
outside the United Kingdom were excluded.
Result: 74 doctors from the United Kingdom, predominantly Consultant Anaesthetists (54%) responded to this
survey. 77% gave some or all of their patients steroids, in 75% of cases at the discretion of the anaesthetist. The
main perceived benefit was to reduce postoperative nausea and vomiting. Diabetics and those deemed at high
risk of wound infection were the group in whom most respondents would be reluctant to give steroids. 32% of
respondents had no concerns. 87% of respondents felt that a randomised trial in this field would be of clinical
interest with most respondents (58%) preferring a three-armed trial – no steroids vs low dose steroids vs high
dose steroids.
Conclusion: This survey indicated that perioperative steroid use is currently widespread. Sufficient equipoise
exists for a trial in this area with regard to examining the impact of dexamethasone on postoperative compli-
cations and the postoperative systemic inflammatory response. Respondents favoured a 3-armed trial – no
steroids vs low-dose steroids vs high-dose steroids.
1. Introduction
Colorectal cancer is the third most commonly diagnosed malignancy
worldwide with approximately 1.8 million new cases being diagnosed
each year [1]. Within the United Kingdom colorectal cancer accounts
for around 16,000 deaths annually [2]. Curative resectional surgery
remains the mainstay of treatment for this condition though carries
with it not only a significant risk of overall morbidity and mortality but
also a significant risk of cancer related mortality even after curative
treatment.
The relationship between an increased postoperative systemic in-
flammatory response and increased likelihood of complications has
now been well documented within the medical literature [3–5] as has
the relationship between the postoperative systemic inflammatory re-
sponse, postoperative complications and long-term oncological
outcome and survival [5–7]. The potential to modulate the post-
operative systemic inflammatory response is therefore of clinical in-
terest as one would hypothesise that this may reduce postoperative
morbidity and mortality and improve long-term cancer free survival.
Single dose corticosteroids are frequently administered in the peri-
operative period to reduce postoperative nausea and vomiting [8–10].
A previous retrospective propensity matched observational study from
our department that included patients undergoing elective resectional
surgery for colorectal cancer demonstrated a reduction in both the
magnitude of the postoperative systemic inflammatory response and
the overall complication rate in those patients who received single dose
dexamethasone on induction of anaesthesia [11]. While a recent large
randomised control trial [10] documented the beneficial effect of single
dose dexamethasone on postoperative nausea and vomiting it did not
measure the postoperative systemic inflammatory response. The
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administration of preoperative corticosteroids appears to be safe with a
previous meta-analysis [12] not demonstrating any association between
preoperative corticosteroid administration and an increased risk of any
complications including anastomotic leaks (p=0.79).
This qualitative questionnaire-based study aimed to examine both
attitudes towards and current practice of perioperative steroid admin-
istration in resectional colorectal surgery. This would improve knowl-
edge of current perioperative steroid use and perceived benefits and
risks of this adjunct to anaesthesia. It would also help to assess whether
there is current equipoise to carry out further research in this area in-
cluding the effect of perioperative steroid use on the postoperative
systemic inflammatory response, morbidity and mortality within the
context of curative colorectal cancer surgery.
2. Methods
This qualitative analysis utilised an internet based survey which was
generated on the SurveyMonkey website [13] and included 9 questions
regarding the use of perioperative steroids in resectional colorectal
cancer surgery (Table 1).
Once this survey was generated, the link to it was publicised on our
department's Twitter feed. Additionally, a list of email addresses was
obtained for surgeons and anaesthetists who have published in this area
and the access link was circulated to them. As only a minority of par-
ticipants were from outside the United Kingdom we decided to exclude
these to provide insight into current use of and attitudes towards
perioperative steroid administration in the United Kingdom.
The survey was circulated in February 2019 and closed for re-
sponses in March 2019. No incentives were used to encourage partici-
pation. Data was analysed and graphs were created using Microsoft
Office and IBM SPSS Statistics Version 24. This study has been regis-
tered with the Research Registry – unique identifier “re-
searchregistry5124”. There are no conflicts of interest or sources of
funding to declare. All responses to this survey were anonymous.
Numerical data has been displayed as numbers and/or percentages
to the nearest whole number. The variation in responses between sur-
geons and anaesthetists have been compared using the Chi squared test
with a two tailed p value of< 0.05 being considered statistically sig-
nificant.
3. Results
Overall, 100 people responded to this survey. 97 people answered
Question 1, 76% (n=74) of whom worked in the UK - only these re-
sponses were included in further analysis.
74 people answered Question 2. 54% of respondents were
Consultant Anaesthetists, 22% Consultant Colorectal Surgeons, 11%
Anaesthetic Trainees, 9% Surgical Trainees and 4% Consultant Non-
Colorectal Surgeons.
70 people answered Question 3. 54% of respondents give some
patients steroids in the perioperative period, 23% give all patients
steroids in the perioperative period, 14% do not give any patients
steroids in the perioperative period and 9% of respondents were unsure
whether their patients receive steroids or not. 48 people provided a free
text comment regarding choice of steroids with greater than 90% using
dexamethasone. The majority of these who specified a dose administer
between 3.3 mg and 8mg of dexamethasone perioperatively.
70 people answered Question 4. Of those whose patients receive
steroids, the decision regarding perioperative steroid use was made by
anaesthetists in 75% of cases, is protocol driven in 12% of cases, made
by a combination of surgeons and anaesthetists in 11% of cases and
made by surgeons in 2% of cases. The remainder do not use perio-
perative steroids.
70 people answered Question 5. Of those who give perioperative
steroids, 90% of respondents administer steroids intraoperatively/on
induction of anaesthesia, 5% give steroids preoperatively and 5% give
steroids postoperatively.
67 people answered Question 6 (Fig. 1). 63% of respondents would
be reluctant to give steroids to insulin-controlled diabetics, 45% to
those deemed at high risk of wound infection, 43% to other diabetics,
16% to emergency cases and 6% to patients with renal failure. 10%
would be reluctant to give steroids to other patients including those
who were septic or at high risk of delirium.
67 people answered Question 7 (Fig. 2). 94% of respondents think
that perioperative steroids reduce postoperative nausea and vomiting,
27% think they reduce the surgical stress response, 10% think they
reduce overall complications, 6% think they have no beneficial effect,
4% think they improve long term survival, 3% think they reduce ana-
stomotic leak rate and 3% think they reduce postoperative mortality.
9% of respondents think that they had other beneficial effects which,
based on free text responses, were predominantly analgesic effects.
66 people answered Question 8 (Fig. 3). 55% of respondents would
be concerned about uncontrolled diabetes/hyperglycaemia, 29% about
Table 1
Questions included in online survey.
Question 1: In which country/region do you work in?
a. United Kingdom d. Australia
b. Europe e. Other (please specify)
c. USA
Question 2: What is your grade and speciality?
a. Anaesthetist (Consultant) e. Consultant Surgeon (Non-Colorectal)
b. Anaesthetist (Trainee) f. Career Grade Surgeon
c. Anaesthetist (Other) g. Surgical Trainee
d. Consultant Surgeon (Colorectal) h. Other (please specify)
Question 3: Do any of your patients receive steroids in the perioperative period?
If yes, please specify the drug and dose or unknown if unsure.
a. Yes (all) c. No
b. Yes (some) a. Unsure
Question 4: If you answered yes to Question 3 who makes the decision regarding
administration of steroids? If you answered no to Question 3 please select N/
A
a.Surgeon d.Part of ERAS or similar protocol
b.Anaesthetist e.N/A
c.Combination
Question 5: If you answered yes to Question 3 when are steroids given to
patients? If you answered no to Question 3 please select N/A
a.Preoperatively c.Post-operatively
b.Intra-operatively/on induction of
anaesthesia
d.N/A
Question 6: Are there any groups of patients to whom you would be reluctant to
give perioperative steroids? (Select all that apply)
a.Diabetics (diet/tablet controlled) d.High risk of wound infection
b.Diabetics (insulin controlled) e.Emergency cases
c.Renal failure f.Other (please specify)
Question 7: Do you think that single dose steroids given perioperatively for
colorectal cancer are associated with? (Select all that apply)
a.Reduced postoperative nausea/
vomiting
e.Reduced postoperative mortality
b.Reduced overall complications f.Improved long term survival
c.Reduced anastomotic leaks g.None of the above
d.Reduced surgical stress response h.Other (please specify)
Question 8: Do you have concerns regarding the use of perioperative single dose
steroids for patients undergoing colorectal cancer resection? (Select all that
apply)
a.Diabetes/hyperglycaemia f.Adrenal complications
b.Increased wound complications g.Gastric complications
c.Increased anastomotic leak rate d.Renal failure
e.Psychiatric/mood problems f.No concerns
g.Insomnia h.Other (please specify)
Question 9: If a trial was set up examining steroid administration at induction of
anaesthesia for colorectal resection, with the aim of addressing the effect on
the postoperative systemic inflammatory response and complications, do you
think there would be sufficient equipoise to recruit for the following: (Please
select all that you feel would be of interest)
a.2-Armed trial – steroids vs no
steroids
c.3-Armed trial – no steroids vs low
dose steroids vs high dose steroids
b.2-Armed trial – low vs high dose
steroids
d.Insufficient equipoise for a trial in
this area
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increased wound complications, 15% about increased psychiatric/
mood disturbance, 11% about insomnia, 8% about increased anasto-
motic leak rate, 5% about increased adrenal complications and 5%
about increased gastric complications. 6% of responders had other
concerns – based on free text comments this was predominantly con-
cern over long term oncological outcomes.
60 people answered Question 9 (Fig. 4). 87% of responders think
there would be sufficient equipoise for a trial in this area. 58% think
there would be sufficient equipoise for a 3-armed trial (no steroids vs
low dose steroids vs high dose steroids), 32% for comparison of steroids
vs no steroids and 13% for low vs high dose steroids. 13% of responders
do not think there would be sufficient equipoise for a trial in this area.
As shown in Table 2 when the responses of surgeons (any grade)
were compared to anaesthetists (any grade) significantly more anaes-
thetists were concerned about giving steroids to non-insulin diabetics
(58% vs 14%, p=0.001) and insulin dependent diabetics (80% vs
27%, p < 0.001). Significantly more anaesthetists were concerned
about uncontrolled diabetes/hyperglycaemia following steroid admin-
istration (73% vs 14%, p < 0.001) and a higher proportion of surgeons
were concerned about the effect of steroids on anastomotic leak rate
(18% vs 2%, p= 0.021). Significantly more surgeons than anaesthetists
had either no concerns or other concerns regarding steroid
administration (55% vs 18% p=0.002).
4. Discussion
The present study was predominantly completed by Consultant
Anaesthetists working in the United Kingdom. The majority of re-
spondents gave some/all of their patients intraoperative steroids with
the decision of whether to administer steroids being at the discretion of
the anaesthetist in most cases. Reduction of postoperative nausea and
vomiting was the primary aim of perioperative steroid administration.
Reluctance to administer steroids was particularly notable for those
patients who are diabetic, particularly insulin dependent and those at
high risk of wound infection. This study suggests that there is sufficient
equipoise to carry out a randomised control trial examining the impact
of dexamethasone on the postoperative systemic inflammatory response
and complications following colorectal resection with respondents in-
dicating that a three-armed trial comprising no steroids vs low dose
steroids vs high dose steroids would be the preferred format for this.
Based on this survey there is concern regarding the use of perio-
perative single dose dexamethasone within the diabetic cohort of pa-
tients, particularly those with insulin dependent diabetes. Two recent
randomised control trials [14,15] have reported a significant increase
Fig. 1. Are there any groups of patients to whom you would be reluctant to give perioperative steroids?.
Fig. 2. Do you think that single dose steroids given perioperatively for colorectal cancer are associated with.
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in blood glucose levels following dexamethasone administration in both
diabetic and non-diabetic patients although there was no significant
difference in the size of the effect between diabetics/non-diabetics in
either study. A recent Cochrane review [16]. Similarly reported an in-
creased blood glucose following dexamethasone however evidence was
limited and there was no evidence of increased negative outcomes as a
result of this although diabetic patients were excluded from most trials.
A previous meta-analysis [12] analysed the impact of corticoster-
oids on both postoperative complications and the postoperative sys-
temic inflammatory response. It reported a significant reduction in both
overall complications and postoperative systemic inflammatory re-
sponse in those patients receiving preoperative corticosteroids although
a significant reduction in infective complications was seen following
surgery for liver but not colorectal malignancy. Similarly, a recent
propensity matched cohort study [11] which included patients under-
going surgery for colorectal cancer reported a significantly lower
postoperative systemic inflammatory response and overall complica-
tions in those patients receiving preoperative dexamethasone. A further
randomised trial [17] of 73 patients undergoing maxillofacial surgery
reported a significant reduction in postoperative CRP rise within the
cohort receiving preoperative dexamethasone.
While a recent large multicentre randomised trial (DREAMS) [10]
reported a significant reduction in postoperative nausea and vomiting
in patients undergoing elective bowel surgery who received single dose
perioperative dexamethasone it did not investigate the difference in
postoperative systemic inflammatory response between groups. Al-
though not limited to colorectal surgery, the PACMAN trial [18] is
currently underway and will include surgical complications. However,
while CRP levels will be collected, postoperative levels of inflammation
are not included as either primary or secondary outcomes. The PADDI
trial [19] is also currently underway and will include surgical site in-
fection as a primary outcome, however this trial neither includes
postoperative inflammation as a primary outcome, nor is limited to
colorectal resections.
Limited literature exists reporting the effect of steroid use on long-
term disease-free survival. One study comparing 515 patients with
stage I-III rectal cancer did report, on multivariate analysis, a reduction
in disease-free and overall survival in those patients receiving in-
travenous dexamethasone A follow up study [20] of a previously con-
ducted small trial of 43 patients undergoing colonic resection also re-
ported a higher rate of distant recurrence in those patients receiving
dexamethasone. However, a recently conducted large propensity mat-
ched study [21] of 2729 patients undergoing breast cancer surgery did
not find an association between perioperative dexamethasone admin-
istration and increased recurrence or mortality. Furthermore, an ob-
servational study [22] of 679 patients undergoing
Fig. 3. Do you have any concerns regarding the use of perioperative single dose steroids for patients undergoing colorectal cancer resection?.
Fig. 4. If a trial was set up examining steroids administered at induction of anaesthesia, do you think there would be sufficient equipoise to assess the following?.
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pancreaticoduodenectomy for cancer reported improved overall sur-
vival in patients given intraoperative dexamethasone.
The present study has a several limitations. This survey is small,
particularly for the subgroup of analysis comparing responses between
surgeons and anaesthetists. To encourage participation in the survey we
intentionally kept survey length short and questions simple.
Furthermore, medical professionals who have a greater interest in ei-
ther perioperative steroid use and evidence based medical practice or
have stronger opinions either for or against perioperative steroid use
were more likely to respond and therefore may bias results.
It would be of interest to examine within a randomised control trial
the effect of steroid administration at induction of anaesthesia on the
postoperative systemic inflammatory response and postoperative short/
long-term outcomes in patients undergoing a curative resection for
colorectal cancer. An observational study by McSorley et al., 2019 [23]
suggested a dose dependent effect of dexamethasone with higher doses
of dexamethasone being associated with a reduced postoperative sys-
temic inflammatory response and postoperative complications. There-
fore, a trial which incorporated a low-dose steroid arm (e.g. dex-
amethasone 4mg) and high-dose steroid arm (e.g. dexamethasone
8mg) would be worthwhile.
In summary, this study has suggested that while most patients
currently receive perioperative steroids with the primary aim of redu-
cing postoperative nausea and vomiting (PONV) they are not used
routinely for all patients. Furthermore, no consensus exists as to the
correct dose, even in the context of the prevention of PONV. Sufficient
equipoise appears to exist for a randomised control trial in colorectal
cancer resection, with a three-armed RCT comparing no steroids vs low
dose steroids vs high dose steroids being the most popular choice of
design. Ideally, anaesthetic technique would be otherwise standardised.
In our opinion such a study should include postoperative complications
as the primary outcome and a measure of the postoperative systemic
inflammatory response (e.g. C-reactive protein) as a secondary out-
come. If included, diabetic patients and those at increased risk of
wound infection would need close monitoring to ensure that they did
not have an unacceptably increased risk of complications. Additionally,
long term follow up of patients included in such a trial would be im-
portant, to identify whether perioperative single dose steroid usage
alters disease free survival, although if not powered for this outcome
then it may remain an area of uncertainty.
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